Sable · Reference
Tirzepatide: UK Research Peptide Reference
Verified reference data for research use only.
Research use only. Not for consumption. No health claims.
Last updated 2026-10-10
Product page · Questions · JSON
Research questions
research_context
Tirzepatide mechanism of action?
In the research literature, Tirzepatide is described as a 39-residue dual GIP and GLP-1 receptor agonist with a C20 fatty diacid moiety, studied in incretin receptor pharmacology. It is classed as a peptide (lipidated). This describes its use as a laboratory research tool only, not any effect in people. Sable Peptides supplies it for laboratory research use only; it is not for human consumption.
Cite this
Plain
Sable Peptides. (2026). Tirzepatide: UK Research Peptide Reference. UK Research Peptide Reference. Retrieved 2026-10-11, from https://www.sablepeptides.co.uk/ref/tirzepatide
APA
Sable Peptides. (2026, October 10). Tirzepatide: UK Research Peptide Reference. UK Research Peptide Reference. https://www.sablepeptides.co.uk/ref/tirzepatide
BibTeX
@misc{sable_tirzepatide_2026, author = {{Sable Peptides}}, title = {{Tirzepatide: UK Research Peptide Reference}}, year = {2026}, howpublished = {\url{https://www.sablepeptides.co.uk/ref/tirzepatide}}, note = {Accessed 2026-10-11. CC BY 4.0}}Badge
<a href="https://www.sablepeptides.co.uk/ref"><img src="https://www.sablepeptides.co.uk/badge/ref.svg" alt="Data: UK Research Peptide Reference — Sable Peptides" width="220" height="40"></a>